SEC Filing Summary: Aziyo Biologics, Inc. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aziyo Biologics, Inc. (the "Company") on June 9, 2023, regarding events occurring on June 8, 2023. The Company is an emerging growth company incorporated in Delaware, with its Class A Common Stock trading on The Nasdaq Capital Market under the symbol "AZYO". The report details the outcomes of the Company's annual meeting of stockholders.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance events rather than financial performance data.
Material Changes and Corporate Actions
- Annual Meeting Attendance: 10,120,917 shares of Class A common stock were present or represented by proxy, representing approximately 85.2% of the outstanding shares as of the April 13, 2023 record date.
- Director Elections (Item 1): David Colpman and Kevin Rakin were elected as Class III directors to serve until the 2026 annual meeting.
- Accounting Firm Ratification (Item 2): Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2023.
- Compensation Plan Approval (Item 3): Stockholders approved the Aziyo Biologics, Inc. Amended and Restated 2020 Incentive Award Plan. The full text of the Plan is filed as Exhibit 10.1.
Voting Results Summary
| Proposal | Votes For | Votes Against/Withheld | Broker Non-Votes | Outcome |
|---|---|---|---|---|
| Election of David Colpman | 8,611,885 | 225,864 (Withheld) | 1,283,168 | Elected |
| Election of Kevin Rakin | 8,325,108 | 512,641 (Withheld) | 1,283,168 | Elected |
| Ratification of PwC | 10,119,179 | 449 (Against) | N/A | Approved |
| 2020 Incentive Award Plan | 8,304,112 | 530,087 (Against) | 1,283,168 | Approved |
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the standard incorporation by reference to the Proxy Statement for details on the Incentive Award Plan. No unusual items or contingencies were disclosed in this specific report.
Key Facts for Investor Verification
- Verify the specific terms and share limits of the newly approved Amended and Restated 2020 Incentive Award Plan in Exhibit 10.1.
- Confirm the tenure of the newly elected Class III directors (David Colpman and Kevin Rakin) extending to 2026.
- Note the high level of broker non-votes (1,283,168 shares) on director elections and the incentive plan, indicating shares held in street name where brokers did not have discretionary voting authority.
- Review the definitive Proxy Statement filed on April 27, 2023, for detailed background on the proposals approved.